Summary
Global Markets Direct’s, ‘Regeneron Pharmaceuticals, Inc. - Product Pipeline Review - 2016’, provides an overview of the Regeneron Pharmaceuticals, Inc.’s pharmaceutical research and development focus.
The report provides comprehensive information on the therapeutics under development by Regeneron Pharmaceuticals, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the pipeline therapeutic landscape of Regeneron Pharmaceuticals, Inc.
- The report provides overview of Regeneron Pharmaceuticals, Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Regeneron Pharmaceuticals, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Regeneron Pharmaceuticals, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
- Evaluate Regeneron Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Regeneron Pharmaceuticals, Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Regeneron Pharmaceuticals, Inc.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
'
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Regeneron Pharmaceuticals, Inc. Snapshot 8
Regeneron Pharmaceuticals, Inc. Overview 8
Key Information 8
Key Facts 8
Regeneron Pharmaceuticals, Inc. - Research and Development Overview 9
Key Therapeutic Areas 9
Regeneron Pharmaceuticals, Inc. - Pipeline Review 12
Pipeline Products by Stage of Development 12
Pipeline Products - Monotherapy 13
Pipeline Products - Combination Treatment Modalities 14
Pipeline Products - Partnered Products 15
Partnered Products/Combination Treatment Modalities 16
Regeneron Pharmaceuticals, Inc. - Pipeline Products Glance 17
Regeneron Pharmaceuticals, Inc. - Late Stage Pipeline Products 17
Pre-Registration Products/Combination Treatment Modalities 17
Phase III Products/Combination Treatment Modalities 18
Regeneron Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 19
Phase II Products/Combination Treatment Modalities 19
Phase I Products/Combination Treatment Modalities 20
Regeneron Pharmaceuticals, Inc. - Early Stage Pipeline Products 21
Preclinical Products/Combination Treatment Modalities 21
Discovery Products/Combination Treatment Modalities 22
Regeneron Pharmaceuticals, Inc. - Drug Profiles 23
aflibercept 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
alirocumab 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
sarilumab 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
dupilumab 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
suptavumab 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
fasinumab 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
(aflibercept + nesvacumab) 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
(aflibercept + rinucumab) 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
evinacumab 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
trevogrumab 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
ziv-aflibercept (recombinant) 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
REGN-19081909 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
REGN-1979 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
REGN-2810 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Monoclonal Antibodies for Ebola Virus Infection 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Monoclonal Antibodies for Middle East Respiratory Syndrome 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Monoclonal Antibody to Agonize GITR for Oncology 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Monoclonal Antibody to Inhibit LAG-3 for Oncology 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Monoclonal Antibody to Inhibit PD-L1 for Oncology 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Oligonucleotides to Inhibit Transthyretin for Amyloidosis 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
REGN-1001 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Monoclonal Antibodies for Blood Cancer and Solid Tumor 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Regeneron Pharmaceuticals, Inc. - Pipeline Analysis 59
Regeneron Pharmaceuticals, Inc. - Pipeline Products by Target 59
Regeneron Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 61
Regeneron Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 62
Regeneron Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 63
Regeneron Pharmaceuticals, Inc. - Recent Pipeline Updates 65
Regeneron Pharmaceuticals, Inc. - Dormant Projects 93
Regeneron Pharmaceuticals, Inc. - Discontinued Pipeline Products 94
Discontinued Pipeline Product Profiles 94
crotedumab 94
dapiclermin 94
enoticumab 94
nesvacumab 94
REGN-1400 94
REGN-846 95
rilonacept 95
ziv-aflibercept (recombinant) 95
Regeneron Pharmaceuticals, Inc. - Company Statement 96
Regeneron Pharmaceuticals, Inc. - Locations And Subsidiaries 98
Head Office 98
Other Locations & Subsidiaries 98
Regeneron Pharmaceuticals, Inc. - Key Manufacturing Facilities 99
Appendix 100
Methodology 100
Coverage 100
Secondary Research 100
Primary Research 100
Expert Panel Validation 100
Contact Us 100
Disclaimer 101
List of Tables
Regeneron Pharmaceuticals, Inc., Key Information 8
Regeneron Pharmaceuticals, Inc., Key Facts 8
Regeneron Pharmaceuticals, Inc. - Pipeline by Indication, 2016 10
Regeneron Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2016 12
Regeneron Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2016 13
Regeneron Pharmaceuticals, Inc. - Combination Treatment Modalities in Pipeline, 2016 14
Regeneron Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2016 15
Regeneron Pharmaceuticals, Inc. - Partnered Products/ Combination Treatment Modalities, 2016 16
Regeneron Pharmaceuticals, Inc. - Pre-Registration, 2016 17
Regeneron Pharmaceuticals, Inc. - Phase III, 2016 18
Regeneron Pharmaceuticals, Inc. - Phase II, 2016 19
Regeneron Pharmaceuticals, Inc. - Phase I, 2016 20
Regeneron Pharmaceuticals, Inc. - Preclinical, 2016 21
Regeneron Pharmaceuticals, Inc. - Discovery, 2016 22
Regeneron Pharmaceuticals, Inc. - Pipeline by Target, 2016 59
Regeneron Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2016 61
Regeneron Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2016 62
Regeneron Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2016 64
Regeneron Pharmaceuticals, Inc. - Recent Pipeline Updates, 2016 65
Regeneron Pharmaceuticals, Inc. - Dormant Developmental Projects,2016 93
Regeneron Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2016 94
Regeneron Pharmaceuticals, Inc., Other Locations 98
Regeneron Pharmaceuticals, Inc., Subsidiaries 98
Regeneron Pharmaceuticals, Inc., Key Manufacturing Facilities 99
List of Figures
Regeneron Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2016 10
Regeneron Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2016 12
Regeneron Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2016 13
Regeneron Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2016 15
Regeneron Pharmaceuticals, Inc. - Pipeline by Top 10 Target, 2016 59
Regeneron Pharmaceuticals, Inc. - Pipeline by Top 10 Route of Administration, 2016 61
Regeneron Pharmaceuticals, Inc. - Pipeline by Top 10 Molecule Type, 2016 62
Regeneron Pharmaceuticals, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016 63
